CanPath

CanPath to study the impact and immune response to COVID-19 infection and vaccination

The Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study is expanding. The Government of Canada is investing $1.9 million through Canada’s COVID-19 Immunity Task Force (CITF) to fund an extension of CanPath’s existing study over a longer period of time, allowing for an additional collection of blood samples and questionnaire responses from participants. [...]

2021-12-01T09:52:04-05:00December 1, 2021|Media Releases|

Canada’s COVID-19 Immunity Task Force funds national study looking at seroprevalence of COVID-19 antibodies among high-risk populations

The Government of Canada is investing $1.9 million through Canada’s COVID-19 Immunity Task Force (CITF) to fund a Canadian Partnership for Tomorrow’s Health (CanPath) study looking at COVID-19 seroprevalence across Canada, with a particular focus on certain populations that are at higher risk of infection.  CanPath is a national population health research platform that follows the health of 330,000 Canadians (or [...]

2021-02-26T10:39:15-05:00October 28, 2020|Media Releases|
Go to Top